Hoth Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 6
- Market Cap
- $5M
- Introduction
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema....
Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Hoth Therapeutics, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT05639933
- Locations
- 🇺🇸
NYU Langone Health, Mineola, New York, United States
🇺🇸UC Irvine - Chao Family Cancer Center, Orange, California, United States
🇺🇸The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Hoth Therapeutics, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04544943
- Locations
- 🇦🇺
Novatrials, Kotara, New South Wales, Australia
© Copyright 2024. All Rights Reserved by MedPath